Scientists and science in the pharmaceutical industry rely heavily on the more academically orientated basic research carried out at Universities, for first of all training, but also as a source of new ideas and approaches to drug discovery. Progress in the discovery and development of novel therapeutics benefits from a healthy alliance with, and the output from, more basic research institutions, and the reverse is also true, with many advances in understanding of physiological and pathological processes being as the result of the application of novel targeted molecules. To illustrate this, some examples related to the themes of this meeting from my experiences in three different companies will be described. The first involves a metabolic angle in the unravelling of the mechanism of the novel anti-anginal agent ranolazine. The second describes the application of detailed knowledge of insulin structure and action to then use recombinant approaches to design novel molecules to be able to offer the Type I (insulin-dependent) diabetic patient therapies allowing a more physiological treatment regime, and also the further application of learned technology to then discover a means of harnessing the potential of GLP-1 (glucagon-like polypeptide 1) for treating Type II (non-insulin-dependent) diabetes. The last illustrates how findings of novel binding sites on glycogen phosphorylase and glucokinase as the result of drug discovery programmes have led to increased understanding of these key metabolic enzymes and also potential new therapies for Type II diabetes.
Introduction
The relationship between the pharmaceutical industry and academia is often complex; however, there is great potential for mutual benefit. The industry firstly relies on academia to provide it with trained researchers, and it was my good fortune to undertake Ph.D. and then postdoctoral studies in Dick Denton's laboratory in Bristol, before embarking on a career firstly as a lecturer, and for the last 15 years in drug discovery. This training gave a strong basis in the topics of this meeting which have been drawn upon continuously and applied in the industrial setting, and also regularly updated by various types of ongoing relationships with the Denton laboratory such as co-supervised Ph.D. studentships. Industry also benefits from advances in basic research at Universities which lead into new areas and targets and technologies, which can then be applied in the search for novel therapeutic agents and approaches. However, academia also benefits from the activities of industry, not only in terms of directly funded research, but also in the availability of novel tools with which to probe physiological and pathological mechanisms, and from the advances in knowledge resulting from the research carried out in companies. For illustrating some of these principles, some examples from my own experiences in industry related to the themes of the meeting are described below.
A metabolic aspect to the action of the anti-anginal agent ranolazine
Ranolazine was discovered by Syntex (where I worked previously) and has been developed further by CV Therapeutics and is now close to market entry as Ranexa TM . Current therapies for angina (and there have been no new therapies for over 25 years) exert their effects by altering haemodynamics and decreasing cardiac work and oxygen demand or increasing cardiac blood flow, whereas ranolazine does not affect haemodynamics and is rather classed as a 'metabolic modulator' and is believed to act by improving the efficiency of the transduction of biochemical energy into contractile work (see [1] ). The regulation of the intramitochondrial PDH (pyruvate dehydrogenase) complex is central to this concept, as activating PDH and switching the source of acetyl-CoA from fatty acids towards pyruvate results in a greater yield of ATP per O 2 and also reduces lactate and H + production, and thus overall leads to improved performance under the restricted flow conditions of angina. PDH is subject to much regulation [2] (Figure 1 ) and this has been studied in the Denton laboratory for many years. PDH can be directly inhibited by its end-products NADH and acetyl-CoA, but in particular the amount of PDHa (active dephosphorylated PDH) is controlled by a dedicated kinase and phosphatase which are themselves regulated. Ranolazine has been found to increase PDHa in cardiac ischaemia models where it The diagram shows different substrate entry points to the acetyl-CoA pool, which were exploited experimentally to identify the mechanism of ranolazine (see text; [1] ). Beta Oxidn, beta oxidation; CPT1, carnitine palmitoyltransferase 1; mito. inner memb., mitochondrial inner membrane; palm.-carn, palmitoyl carnitine; TCA, tricarboxylic acid.
also improves cardiac performance [3, 4] , and coincidental increases in glucose oxidation and decreases in fatty acid oxidation have been described [5, 6] . As to the underlying mechanism, studies revealed that ranolazine decreased acetylCoA content in hearts perfused with palmitate and also with octanoate (which does not require carnitine palmitoyl transferase I to access the mitochondrial matrix), but not with acetate, which feeds directly into the acetyl-CoA pool. With octanoate, observed increases in C 8 , C 6 and C 4 CoA esters suggested inhibition of fatty acid β-oxidation as the site of action [4] and indeed the term 'partial fatty acid oxidation', or pFOX, inhibitors was coined, with ranolazine as the prototypical agent of this new drug class [7, 8] . With ranolazine, there is good evidence linking this mechanism to its anti-ischaemic efficacy; however, another mechanism(s) may also play a role (see [8] ), including the finding that it is a weak inhibitor of the respiratory complex I, but with much greater potency in broken or uncoupled mitochondria than in coupled mitochondria [9] .
Designing insulins to improve treatment for diabetes
The Denton laboratory has explored many aspects of insulin action over the years, and I next worked at Novo-Nordisk, which has been at the forefront of the production of, but also research on, insulin for many decades, and work in its labo- ratories has often led the whole field. The normal physiology of insulin is that there is always a basal level in the bloodstream, and then in response to meals and to cover glucose clearance from the blood, there are peaks of insulin [10] ( Figure 2 ). Although human insulin has now been available for over 20 years, there remained the problem that by subcutaneous injection and the kinetics of absorption it was still very difficult to match this physiology [11] . However, the intimate knowledge generated of the structure and crystal packing of insulin at Novo-Nordisk allowed the identification of sites on insulin which could be modulated without affecting its biological properties, but would affect the monomer/hexamer equilibrium. By application of recombinant DNA technology to produce novel insulins in yeast, this led to the production of the rapid acting insulin analogue insulin aspart (B28Asp human insulin; NovoRapid R or NovoLog R ) [11, 12] . This designed insulin analogue is thus more rapidly absorbed from injection sites into the bloodstream and also has a profile with a reduced 'tail', meaning that it can be injected just prior to a meal, has a profile that matches the normal physiology, and also does not remain for too long in the bloodstream, thus reducing the likelihood of hypoglycaemia between meals, and in the long term leads to reductions in HbA1c (glycated haemoglobin) indicating better overall blood glucose control [11, 12] . Regarding basal insulin replacement, NPH (neutral protamine Hagedorn) isophane preparations of insulins which form insoluble crystalline suspensions have been used for over 50 years to provide 24 h basal plasma levels; however, its absorption kinetics are not ideal [13] . By using its knowledge of insulin and by implementing a novel technology approach, Novo-Nordisk designed an acylated insulin analogue, which then binds to albumin to create a long-lasting reservoir which is in equilibrium with a small free concentration available for receptor binding. Insulin Detemir [B29Lys(epsilontetradecanoyl),desB30 human insulin; Levemir R ] [12] [13] [14] thus has a flatter absorption profile, and as it is a soluble preparation, also has more reproducible dosing, and again has led to improvements in overall blood glucose control while at the same time reducing occurrences of hypoglycaemia [13, 14] . The availability of these designed insulins, produced on the 
Harnessing the potential of GLP-1 (glucagon-like polypeptide 1)
GLP-1 is an incretin hormone that potentially offers an ideal treatment for Type II diabetic patients: it only enhances insulin release when blood glucose is raised (i.e. there is no risk of hypoglycaemia); it reduces glucagon secretion (thus having a marked effect on insulin/glucagon ratio); it is mitogenic on pancreatic β-cells (and thus may address the main underlying defect of erosion of β-cell capability as the disease progresses [15] ); and, via its effects on gut motility, it reduces appetite (thus leading to weight loss) [16] . The problem with native GLP-1 is that it has a very short halflife (∼2 min) as it is rapidly degraded by DPPIV (dipeptidyl peptidase IV) and this initial promise was demonstrated using continuous infusion of the hormone, which revealed that 24 h presence was needed [17] . Thus the pharmaceutical industry is developing both DPPIV inhibitors (this enzyme also processes many other substrates) and longer-acting GLP-1 analogues [18] . The approach adopted at NovoNordisk was to develop further what had been learned with insulin (see above) and also create an acylated GLP-1 [Liraglutide; NN2211; Arg 34 Lys
GLP-1-(7-37)] which retained full biological activity and was also found to be resistant to DPPIV, and has its half-life extended to approx. 10-12 h, making it suitable for once-daily injection [19, 20] . This is now in Phase 2 clinical development, and exanitide (Byetta TM ) [21] from Lilly/ Amylin, which is a synthetic derivative of exendin-4, a protein found in the salivary gland of the venomous Gila monster lizard, and which is similarly targeted, was approved recently by the U.S. FDA (Food and Drug Administration) [22] .
Using drug molecules to define new binding sites on GK (glucokinase) and GP (glycogen phosphorylase)
The liver is a key tissue in overall metabolic regulation, a lifelong interest of Dick Denton [23] , and it is not surprising that liver targets have been approached in drug discovery programmes, as derangements in liver metabolism underlie some of the metabolic defects in diseases such as Type II diabetes, where the inappropriate hepatic overproduction of glucose clearly contributes to the disease [24] . I am now working at Prosidion Ltd, and this company has a GP inhibitor and a GK activator (Figure 3 ) scheduled to enter clinical development this year. These enzymes have a high control strength over liver glucose metabolism [25] , suggesting that they would be optimal targets for drug intervention, and GK is additionally present in pancreatic β-cells where it plays a similar 'glucose sensor' role as in the liver [26] . The interest here is that this serves as an illustration of how the availability of novel drug molecules can lead to discovery of novel elements of key enzymes, and in each case novel binding sites have been defined. GP, which exists as a dimer, catalyses the rate-limiting step in the overall process of glycogenolysis and exists as three isoforms in mammals designated brain, skeletal muscle and liver isoforms, each encoded by a separate gene located on different chromosomes [24] . Like PDH, it is subjected to much regulation, and in particular it is phosphorylated (at Ser 14 ) to form the more active GPa in response to hormones such as glucagon and adrenaline, whereas insulin leads to its dephosphorylation to form GPb, though both GPa and GPb have inactive (T) and active (R) conformations [24] . Likewise, different inhibitors of GP inhibit the enzyme in different ways, and there are five known binding sites for inhibitors [24] , including the allosteric inhibitor site [27] that was identified via the availability of new inhibitor molecules arising from drug discovery programmes [28] . This site is located at the interface between the two subunits in the region of the central cavity of the dimeric structure and is approx. 33 Å (1 Å = 0.1 nm) distance from the catalytic site. It is not known if there are physiological effectors of GP that bind this site. The different inhibitor classes result in different inhibitory profiles such as different impacts on GPa and GPb and R and T conformations, and differential glucose dependence [24, 29] . There is also the idea that an inhibitor of GP might also lead to inhibition of gluconeogenesis, as there is the hypothesis that there is flux of gluconeogenically produced glucose through glycogen [30] ; however, other data are at variance with this [31] .
GK (also called hexokinase IV) has a lower affinity for glucose than other hexokinases, in the range of prevailing blood glucose levels, and sigmoidal kinetics, which underlie its role as a 'glucose-sensor' in liver and in pancreatic β-cells [32, 33] . In the liver, but not in β-cells, there is also a GK regulatory protein that inhibits GK competitively with glucose, and also plays a role in determining the localization of GK in the cell, for example, sequestering it to the nucleus in the fasting state [33] . Inactivating mutations on one allele of GK have long been known to be the underlying cause of maturity-onset diabetes of the young type II, whereas two affected alleles cause permanent neonatal diabetes, and some rare activating mutations have also been described which cause the persistent hyperinsulinaemic hypoglycaemia of infancy syndrome [34] [35] [36] [37] . Several gene knockout and transgenic overexpression studies in mice have also confirmed the important role of GK (see ). A drug discovery programme at Roche [42] [43] [44] led to the discovery of a novel allosteric activating site on GK that has been followed by programmes at other companies, including Prosidion. Both K m and/or V max may be affected and crystallographic studies have shown that the same region and similar conformational changes of the enzyme are involved as in the activating mutations [42] [43] [44] [45] . Other hexokinases are not affected as only GK possesses this allosteric binding pocket identified with the activators. The availability of GK activators may allow the potential always inherent in GK as a target in both the pancreatic β-cell and the liver to now be realized.
Conclusions
In summary, the basic research carried out in Dick Denton's and other similar laboratories into the fundamental regulatory mechanisms involved in cell metabolism and hormone action thereon, under both normal physiology and disease pathology settings, has led to the identification of targets and means whereby the pharmaceutical industry can apply its skills and processes to the discovery and development of novel treatments to combat human disease. Conversely, application of the drug tools made available through such industrial endeavours back within the more academic laboratory have in many instances enabled further understanding of such physiological and pathological mechanisms.
